



**Centre of Regulatory Excellence
@ Duke-NUS Medical School**

GRADUATE CERTIFICATE IN PHARMACEUTICAL REGULATION

GMS5105: Generic Medicines

13 July – 17 July 2020

Venue: Zoom

WORKSHOP PROGRAMME

Overall objectives of the workshop

- Build and enhance capability for the key activities and roles essential for effective regulation of generic medicines
- Promote opportunities for optimisation of regulatory cooperation and networking within ASEAN region

Learning outcomes

- Explain the principles and regulatory requirements for a generic medicinal product and the differences from an innovator product
- Describe the fundamental principles for evaluating quality and clinical aspects of a generic medicine
- Describe contemporary approaches and considerations for assessing bioequivalence of different dosage forms
- List the initiatives that are promoting efficiency and effectiveness through regulatory cooperation

Copyright statement

This material is the property of the Duke-NUS Medical School. It is not to be duplicated or distributed without written permission of the Executive Director and the management team of the Centre of Regulatory Excellence of Duke-NUS Medical School.

Graduate Certificate in Pharmaceutical Regulation

GMS5105: Generic Medicines

13 – 17 July 2020

Day 1 – 13 July, Mon

Topic	Speaker/ Organisation
8.00am Registration	
Session 1: Regulatory Management of Generic Medicines	
9.00am Welcome Graduate Certificate Students	Prof John Lim Executive Director Centre of Regulatory Excellence (CoRE) Duke-NUS Medical School
9.15am Workshop Briefing	Asst Prof James Leong Head of Pharmaceutical Science Programme Centre of Regulatory Excellence Duke-NUS Medical School
9.30am Regulatory Frameworks for Generics <ul style="list-style-type: none"> Overview of the regulatory requirements of major regulators and Asia Pacific region 	Dr Jin Shun Head, Regulatory Affairs APMA Sandoz
10.30am Refreshment Break	
11.00am Regulatory Guidelines for Generics <ul style="list-style-type: none"> Key references for submission and evaluation of generics 	Dr Henrike Potthast Biopharmaceutics Expert Pharmacokinetics Federal Institute for Drugs and Medical Devices (BfArM) Germany
11.45am Dossier Requirements for Generics <ul style="list-style-type: none"> ICH CTD and ACTD ASEAN Technical Guidelines 	
12.30pm Lunch	
1.30pm Case Discussion <ul style="list-style-type: none"> Identify differences in regulatory requirements among major regulators and ASEAN regulators 	
3.00pm Refreshment Break	
3.30pm Contemporary Issues in Generic Medicines Development <ul style="list-style-type: none"> Patent enforcement and Intellectual Property Trends in generics product developments 	Dr Stefanie Amend-Mall Head Global Project Management Office PD (Product Development) Sandoz
4.15pm Challenges in Regulatory Management of Generics <ul style="list-style-type: none"> Different dosage forms Divergence in requirements Infringement of patents and IP 	
5.00pm End	

GMS5105: Generic Medicines (13 – 17 July 2020)

**The Programme is accurate as of 8 June 2020 and may be subjected to further refinement if necessary before the actual workshop.*

Day 2 – 14 July, Tue

	Topic	Speaker/ Organisation
8.30am	Individual and Group assessment I	
10.00am	Refreshment Break	
Session 2: Quality Requirements and Assessment of Generics		
10.30am	Guidelines and Regulatory Requirements for Quality Aspects of Generics	
11.15am	Standards and Use of Pharmacopeia in the Regulatory Management of Generics	Dr Sharad Mankumare Director RSL and Verification Programs The United States Pharmacopeia (USP) India
11.45am	In-Vitro Dissolution Studies <ul style="list-style-type: none"> • Utility of dissolution studies for assessment of generics • Design and dissolution procedures 	
12.30pm	Lunch	
1.30pm	In-Vitro Dissolution Studies (cont'd) <ul style="list-style-type: none"> • Dissolution conditions for various dosage forms, including modified release 	
2.15pm	Briefing for Practicum 1	
2.30pm	Refreshment Break	
3.00pm	Practicum 1 <ul style="list-style-type: none"> • Evaluation of quality data for regulatory approval 	
4.30pm	Group presentation and Discussion for Practicum 1	
5.00pm	End	

GMS5105: Generic Medicines (13 – 17 July 2020)

**The Programme is accurate as of 8 June 2020 and may be subjected to further refinement if necessary before the actual workshop.*

Day 3 – 15 July, Wed

	Topic	Speaker/ Organisation
8.30am	Individual and Group assessment II	
10.00am	Refreshment Break	
Session 3: Clinical Requirements and Assessment of Generics		
10.30am	Guidelines and Regulatory Requirements for Clinical Aspects of Generics	Dr Jan Welink Chair Pharmacokinetics Working Party European Medicines Agency Senior Clinical Assessor Medicines Evaluation Board (MEB)
11.00am	Assessing Bioavailability and Bioequivalence (BABE) <ul style="list-style-type: none"> • Study Designs • Evaluation of BABE, including modified release dosage forms 	Dr Jan Welink MEB
12.30pm	Lunch	
1.00pm	Bioanalytical Studies for Assessing BABE <ul style="list-style-type: none"> • Standards, calibration and controls • Methods and Validation 	Dr Jan Welink MEB
2.15pm	Briefing for Practicum 2	
2.30pm	Refreshment Break	
3.30pm	Practicum 2 <ul style="list-style-type: none"> • Assessment of BABE data for regulatory approval 	Dr Jan Welink MEB
4.30pm	Group Presentation and Discussion for Practicum 2	
5.00pm	End	

GMS5105: Generic Medicines (13 – 17 July 2020)

**The Programme is accurate as of 8 June 2020 and may be subjected to further refinement if necessary before the actual workshop.*

Day 4 – 16 July, Thurs

	Topic	Speaker/ Organisation
8.30am	Individual and Group assessment III	
10.30am	Refreshment Break	
Session 4: Advanced Approaches and Different Dosage Forms		
10.30am	Overview of Dosage Forms in Generic Medicines Development	Dr Henrike Potthast BfArM
11.00am	Approaches and challenges for different dosage forms <ul style="list-style-type: none"> • Orodispersible tablets • Transdermal patches and topicals • Inhalers and nasal sprays • Depot injections 	Dr Henrike Potthast BfArM
12.30pm	Lunch	
1.30pm	BCS-based Biowaivers <ul style="list-style-type: none"> • Guidelines and recommendations • Technical and documentary requirements • (differentiate IVIVCs) 	Dr Henrike Potthast BfArM
2.15pm	Briefing for Practicum 3	
2.30pm	Refreshment Break	
3.00pm	Practicum 3 <ul style="list-style-type: none"> • BCS waivers to support regulatory decisions 	Dr Henrike Potthast BfArM
4.30pm	Group presentation and Discussion for Practicum 3	
5.00pm	End	

GMS5105: Generic Medicines (13 – 17 July 2020)

**The Programme is accurate as of 8 June 2020 and may be subjected to further refinement if necessary before the actual workshop.*

Day 5 – 17 July, Fri

	Topic	Speaker/ Organisation
9.00am	End of Module Assessment	
10.00am	Discussion	
10.30am	Refreshment Break	
Session 5: Improving the Regulatory Management of Generics		
11.00am	Ensuring Quality Control for Generics <ul style="list-style-type: none"> GMP compliance Quality Management System 	Mr Lakshmana Murthy Director Quality Assurance United States Pharmacopeia (USP) India
11.45am	Lunch	
1.00pm	Regulatory Cooperation: Work-sharing Initiatives for Generics in ASEAN	
1.30pm	ACSS – Generics	
2.00pm	Tea Break	
2.30pm	Panel Discussion - Post-Market Activities for Generics <ul style="list-style-type: none"> Alignment of post-market commitments of innovator products Pharmacovigilance of generics Concerns in interchangeability 	
3.45pm	Business and Regulatory Strategy for Developing Generics	
4.30pm	Q&A	
4.45pm	Graduate Certificate Workshop Conclusion	A/Prof Silke Vogel Deputy Director, CoRE Senior Associate Dean Graduate Studies Duke-NUS Medical School
5.00 pm	End	

GMS5105: Generic Medicines (13 – 17 July 2020)

**The Programme is accurate as of 8 June 2020 and may be subjected to further refinement if necessary before the actual workshop.*